Suppr超能文献

用于人类红细胞从B血型血清转化为O血型的重组α-半乳糖苷酶的特性研究。

Characterization of recombinant alpha-galactosidase for use in seroconversion from blood group B to O of human erythrocytes.

作者信息

Zhu A, Leng L, Monahan C, Zhang Z, Hurst R, Lenny L, Goldstein J

机构信息

Lindsley F. Kimball Research Institute, The New York Blood Center, 10021, USA.

出版信息

Arch Biochem Biophys. 1996 Mar 15;327(2):324-9. doi: 10.1006/abbi.1996.0129.

Abstract

Alpha-Galactosidase (alpha-GAL) purified from green coffee bean cleaves the terminal galactose residues from the surface of group B erythrocytes, thereby converting these cells serologically to group O cells. Such enzymatically converted red cells have been transfused into group A and O recipients as part of the first phase of FDA-approved clinical trials. Recently we expressed the recombinant alpha-GAL (r)alpha-GAL) in large quantities in a methylotrophic yeast strain Pichia pastoris and purified the protein to apparent homogeneity by chromatography on a macro prep S50 column. Purified (r)alpha-GAL, migrating as a single band of 41 kDa on a SDS-PAGE, appears to be identical to its native counterpart in specific activity (32 U/mg) and kinetic parameters (K(m) =0.363 mM and V(max) = 46.9 U/mg). Both enzymes demonstrate the same pH profile in the pH range from 2 to 9, with an optimal pH at 6.4 when tested with the substrate p-nitrophenol-alpha-D-galactopyranoside. Furthermore, as with its native counterpart, (r)alpha-GAL specifically cleaves alpha-linked terminal galactose residues from group B red cells without affecting other major antigens on the red cell surface. In addition, we developed a method for using RT-PCR to detect possible DNA contamination in the purified protein preparation, which is one of the concerns for in vivo studies. Thus, with a simple procedure for over-expression and purification of (r)alpha-GAL from P. pastoris culture, one can readily obtain the enzyme needed for large-scale sero-conversion of red cells.

摘要

从绿咖啡豆中纯化得到的α-半乳糖苷酶(α-GAL)可切割B型红细胞表面的末端半乳糖残基,从而将这些细胞血清学转化为O型细胞。作为美国食品药品监督管理局(FDA)批准的临床试验第一阶段的一部分,这种经酶促转化的红细胞已被输注给A型和O型受血者。最近,我们在甲基营养酵母菌株巴斯德毕赤酵母中大量表达了重组α-GAL(rα-GAL),并通过在Macro Prep S50柱上进行层析将该蛋白纯化至表观均一性。纯化后的rα-GAL在SDS-PAGE上迁移为一条41 kDa的单带,其比活性(32 U/mg)和动力学参数(K(m)=0.363 mM,V(max)=46.9 U/mg)似乎与其天然对应物相同。当用底物对硝基苯酚-α-D-吡喃半乳糖苷进行测试时,两种酶在pH值2至9的范围内都表现出相同的pH曲线,最佳pH值为6.4。此外,与天然对应物一样,rα-GAL可特异性切割B型红细胞表面的α-连接末端半乳糖残基,而不影响红细胞表面的其他主要抗原。此外,我们开发了一种使用RT-PCR检测纯化蛋白制剂中可能存在的DNA污染的方法,这是体内研究关注的问题之一。因此,通过一个从巴斯德毕赤酵母培养物中过表达和纯化rα-GAL的简单程序,人们可以很容易地获得红细胞大规模血清学转化所需的酶。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验